Completion of 160 tests conducted in less than 90 minutes demonstrates a level of speed and efficiency beyond the limits of traditional testing approachesNEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of a high-volume workforce drug test for Barcaldine Regional Council in remote Queensland, Australia, (the “ ...

Company surpasses 450 accounts across 24 countries as global demand for fingerprint drug testing surgesNEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced recent growth highlights across its global operations, driven by new account acquisitions, expansion into new testing areas and sectors, and continued penetration into safety-critical i ...

EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 INTELLIGENT BIO SOLUTIONS INC. 2019 Long Term Incentive Plan As Amended and Restated May 8, 2025 Section 1. Purpose; Definitions. 1.1. Purpose. The purpose of the Plan is to enable the Company to offer to employees, officers and directors of and consultants to the Company and its Subsidiaries and Affiliates whose past, present and/or potential future contributions to the Company and its Subsidiaries have been, are or will be important to the success of the Company, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-39825 Intelligent Bio Solutions Inc. (Exact name of Registrant as specified in its Charter) (State or other jurisdic ...

20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended March 31, 2025 35 new accounts and international growth during Q3 bring total active accounts to over 450 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive t ...

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has integrated Arabic as the second international language to its Intelligent Fingerprinting Drug Screening System as part of the Company's multilingual upgrade. The addition of Arabic follows INBS's previously announced expansion plans in the Middle East in early 2025, through its ...

NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its participation as a gold sponsor at the 2025 National Drug and Alcohol Screening Association (NDASA) Conference and Trade Show, taking place from April 1 – 4 in Jacksonville, Florida. Daniel Brown, Head of Clinical Affairs at Intelligent Bio Solutions, will present at the Internation ...

Company Overview - Intelligent Bio Solutions Inc. (INBS) has secured a key patent in the United States for its Intelligent Fingerprinting Drug Screening Cartridge, marking its sixth active patent in the U.S. [1][4] - The company aims to enhance its competitive edge and accelerate the commercialization of its technology as it approaches market launch [2][4]. Market Position and Financials - INBS currently has a market capitalization of $11.9 billion and anticipates an earnings growth of 80.4% in 2025 [5]. - Following the patent announcement, INBS shares fell by 5.1%, closing at $1.67, with a 6-month decline of 8.2%, compared to the industry's 13.2% decline [3]. Product and Technology - The Intelligent Fingerprinting Drug Screening Cartridge is a non-invasive drug testing solution that detects drug metabolites through fingerprint sweat analysis, offering rapid and hygienic screening [9][10]. - The cartridge collects a small sweat sample and provides results in minutes, eliminating the need for invasive sample collection and reducing contamination risks [10]. Intellectual Property and Competitive Advantage - INBS has developed a robust intellectual property portfolio, with six active U.S. patents covering various aspects of its drug screening technology [6][8]. - The strengthened IP protection reduces imitation risks and reinforces investor confidence in the company's long-term growth potential [4]. Industry Prospects - The global drug screening market was valued at $7.7 billion in 2023 and is projected to grow at a CAGR of 16.6%, reaching $19.5 billion by 2029, positioning INBS to capitalize on this growth with its patented technology [11].

INBS set to capitalize on growing Spanish Drug Testing Market, anticipated to reach $448 million by 2030 Major Spanish accounts currently require 1,000 drug testing cartridges per month NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has expanded access to its fingerprint drug testing in Spain and Andorra through a strategic coll ...

Core Viewpoint - Intelligent Bio Solutions Inc. has been granted its sixth U.S. patent, enhancing its intellectual property portfolio and competitive position as it prepares to enter the multi-billion dollar U.S. drug screening market in 2025 [1][3]. Company Overview - Intelligent Bio Solutions Inc. is a medical technology company focused on delivering intelligent, rapid, non-invasive testing solutions, particularly through its Intelligent Fingerprinting Drug Screening System [4]. - The company aims to revolutionize portable testing via fingerprint sweat analysis, which is designed to be hygienic and cost-effective [4]. Patent Details - The newly granted U.S. Patent No. 12259385 pertains to the proprietary lateral flow test strip within the Drug Screening Cartridge, ensuring protection for all current and future products developed by the company [2]. - This patent is fundamental to the company's testing system, which utilizes lateral flow technology to detect drugs in fingerprint sweat [2]. Market Position and Strategy - The U.S. market is identified as a key focus for the company, with plans to enter this market in 2025, supported by the recent FDA 510(k) submission in December 2024 [3]. - The Intelligent Fingerprinting Drug Testing Solution addresses the growing demand for drug testing in safety-sensitive industries, providing a non-invasive alternative that supports employee well-being and compliance [3]. Target Industries - Current customer segments outside the U.S. include construction, manufacturing, engineering, transport and logistics, drug treatment organizations, and coroners [4].